Vera Therapeutics' Upcoming Investor Engagements
Vera Therapeutics, Inc. (NASDAQ: VERA), recognized for its commitment to advancing transformative treatments in the field of immunological diseases, has officially announced its participation in a series of significant investor conferences. This engagement highlights the company's ongoing mission to connect with stakeholders and showcase its groundbreaking research.
Details of the Investor Conferences
The investor conferences will provide an opportunity for Vera's management team to present their innovative approaches and engage in one-on-one discussions with potential investors.
Cantor Global Healthcare Conference
The Cantor Global Healthcare Conference will take place on a Thursday, featuring a unique format that includes a fireside chat along with one-on-one meetings. The company aims to present insights into its latest advancements, strategies for growth, and potential market opportunities.
Morgan Stanley 23rd Annual Global Healthcare Conference
Shortly after, the Morgan Stanley Annual Global Healthcare Conference will occur on Monday. Here, Vera will also engage in a fireside chat and individual meetings to discuss its clinical advancements and future prospects in immunology.
Webcast Details
A replay of the company’s presentations will be accessible for 90 days. Interested parties can view the webcasts through the investor calendar section available on Vera's official website. This accessibility ensures that stakeholders can catch up on critical information and insights shared during the conferences.
About Vera Therapeutics
Vera Therapeutics is dedicated to developing innovative solutions to address severe immunological diseases. With its lead product candidate, atacicept, Vera aims to change the standard of care in treating conditions such as immunoglobulin A nephropathy (IgAN) and lupus nephritis. Atacicept functions as a fusion protein administered once weekly via subcutaneous injection, effectively blocking the proteins BAFF and APRIL, which play pivotal roles in B cell activation and autoantibody production.
Furthermore, Vera holds a unique license agreement with Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL, indicating broad therapeutic potential across B cell-mediated diseases. Additionally, the company is actively developing MAU868, a monoclonal antibody targeting BK virus infection, a significant concern particularly in patients undergoing kidney transplants.
Contact Information
For further inquiries or clarifications regarding Vera's developments, investors are encouraged to reach out to:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
Email: jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
Email: corporatecommunications@veratx.com
Frequently Asked Questions
What are the upcoming conferences Vera is attending?
Vera Therapeutics will be attending the Cantor Global Healthcare Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference.
How can I watch the presentations?
The presentations will be available for replay on Vera's official website for 90 days following the events.
What is Vera's lead product candidate?
Atacicept is Vera Therapeutics' lead product candidate, designed to target immune responses in autoimmune diseases.
What other products is Vera developing?
Vera is also developing MAU868, aimed at neutralizing BK virus infection, among other innovations in immunological treatment.
Who can I contact for investor information?
For investor-related inquiries, you can contact Joyce Allaire at LifeSci Advisors via phone or email.